MedTrace Logo

A Study of PYX-201 in Advanced Solid Tumors

NCT05720117 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 330

Last updated 2026-03-20

No results posted yet for this study

Summary

The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.

Conditions

Interventions

DRUG

PYX-201

Antibody-Drug Conjugate

Sponsors & Collaborators

  • Pyxis Oncology, Inc

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-14
Primary Completion
2026-07-31
Completion
2027-05-31
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05720117 on ClinicalTrials.gov